Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06133075 · ClinicalTrials.gov registry record · Phase 2
Using Mirabegron to Increase BP in Patients With POTS
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT06133075 is a Phase 2 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT06133075, a Phase 2 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments. The American Heart Association funds this study.
Interventions
- DRUG Mirabegron 50 MG
- DRUG Mirabegron 25 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-12-22 |
| Est. Completion | 2025-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06133075
The ClinicalTrials.gov registry entry for NCT06133075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mirabegron 50 MG is the first listed.
NCT06133075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06133075 about?
NCT06133075 is a clinical study titled "Using Mirabegron to Increase BP in Patients With POTS". This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycar...
What is the current status of trial NCT06133075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-12-22. Estimated completion is 2025-07-25.
What interventions are being tested in trial NCT06133075?
The interventions under investigation include: Mirabegron 50 MG (DRUG), Mirabegron 25 MG (DRUG).
Who is sponsoring clinical trial NCT06133075?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.